Literature DB >> 23696927

Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer.

Xiaowen Shao1, Wenjie Mei, Wenhao Weng, Jinlong Qin, Jianhong Zhou, Jie Liu, Jiajing Cheng.   

Abstract

UNLABELLED: Ovarian cancer is one of the most common gynecological malignancies. Limited efficacy of cytotoxic chemotherapy is a key obstacle in the treatment of advanced ovarian cancer. This study aimed to investigate whether Mir-375 enhances Rawq01 (a ruthenium derived compound) induced cell death in ovarian cancer.
METHODS: Three human ovarian cancer cell lines were selected, and independently treated with Rawq01+mir-375 and Rawq01+control. MTT assay and flow cytometry were performed to detect the growth of ovarian cancer cells. Western blot was carried out to determine the expression of apoptotic associated proteins. In addition, ovarian cancer xenografts were established to explore whether mir-375 increased the in vivo chemosensitivity of ovarian cancer cells to RAWQ01.
RESULTS: Over-expression of mir-375 sensitized the ovarian cancer cells to RAWQ01. Mir-375 enhanced the in vitro sensitivity of ovarian cancer cells to RAWQ01 by inducing apoptosis. Mir-375 also increased the in vivo chemosensitivity of ovarian cancer cells to RAWQ01.
CONCLUSION: Mir-375 can enhance Rawq01 induced cell death in human ovarian cancer both in vitro and in vivo.

Entities:  

Keywords:  Ovarian cancer; Rawq01; mir-375; ruthenium derived compound

Mesh:

Substances:

Year:  2013        PMID: 23696927      PMCID: PMC3657362     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  31 in total

1.  A triphenylamine-grafted imidazo[4,5-f][1,10]phenanthroline ruthenium(II) complex: acid-base and photoelectric properties.

Authors:  Su-Hua Fan; An-Guo Zhang; Chuan-Chuan Ju; Li-Hua Gao; Ke-Zhi Wang
Journal:  Inorg Chem       Date:  2010-04-19       Impact factor: 5.165

2.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

3.  Epigenetic silencing of microRNA-375 regulates PDK1 expression in esophageal cancer.

Authors:  Xiaoli Li; Rui Lin; Jiansheng Li
Journal:  Dig Dis Sci       Date:  2011-04-30       Impact factor: 3.199

Review 4.  MYC oncogenes and human neoplastic disease.

Authors:  C E Nesbit; J M Tersak; E V Prochownik
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

Review 5.  Insights into the potential use of microRNAs as biomarker in cancer.

Authors:  Mohammad Iffat Kabir Anindo; Ahmed Yaqinuddin
Journal:  Int J Surg       Date:  2012-08-17       Impact factor: 6.071

6.  Decreased expression of microRNA-375 in nonsmall cell lung cancer and its clinical significance.

Authors:  Y Li; Q Jiang; N Xia; H Yang; C Hu
Journal:  J Int Med Res       Date:  2012       Impact factor: 1.671

7.  Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes.

Authors:  Wenbing Hu; Qun Luo; Xiaoyan Ma; Kui Wu; Jianan Liu; Yi Chen; Shaoxiang Xiong; Jianping Wang; Peter J Sadler; Fuyi Wang
Journal:  Chemistry       Date:  2009-07-06       Impact factor: 5.236

8.  miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.

Authors:  Lin Xia; Dexin Zhang; Rui Du; Yanglin Pan; Lina Zhao; Shiren Sun; Liu Hong; Jie Liu; Daiming Fan
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

Review 9.  Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer.

Authors:  Franco Muggia
Journal:  Gynecol Oncol       Date:  2008-10-31       Impact factor: 5.482

10.  Metal complexes as DNA intercalators.

Authors:  Hong-Ke Liu; Peter J Sadler
Journal:  Acc Chem Res       Date:  2011-03-29       Impact factor: 22.384

View more
  3 in total

1.  Mechanism of MicroRNA-375 Promoter Methylation in Promoting Ovarian Cancer Cell Malignancy.

Authors:  Junjun Shu; Ling Xiao; Sanhua Yan; Boqun Fan; Xia Zou; Jun Yang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

2.  Emblica officinalis extract downregulates pro-angiogenic molecules via upregulation of cellular and exosomal miR-375 in human ovarian cancer cells.

Authors:  Alok De; Benjamin Powers; Archana De; Jianping Zhou; Siddarth Sharma; Peter Van Veldhuizen; Ajay Bansal; Ramratan Sharma; Mukut Sharma
Journal:  Oncotarget       Date:  2016-05-24

3.  Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data.

Authors:  Fenghao Sun; Xiaodong Yang; Yulin Jin; Li Chen; Lin Wang; Mengkun Shi; Cheng Zhan; Yu Shi; Qun Wang
Journal:  Mol Med Rep       Date:  2017-05-25       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.